Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara

Petri, Marcelo H.; Satoh, Minoru; Martín-Márquez, Beatriz Teresita; Vargas-Ramírez, R; Jara, Luis J.; Saavedra, Miguel Ángel; Cruz-Gonzalez, Claudia; Andrade-Ortega, Lilia; Vera‐Lastra, Olga; Salazar-Páramo, Mario; Prieto-Parra, Rosa E; González-López, Laura; Gámez-Nava, Jorge I.; Ramírez-Sánchez, Hermes Ulises; Chan, Jason Y F; Ross, Steven J.; Chan, Edward K. L.; Mercado, Mónica Vázquez-Del

doi:10.1186/ar4207

Cited by 69 publications

(68 citation statements)

References 28 publications

(52 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interestingly, a recent study showed that US juvenile patients with DM and relatively high historical UV exposure are at higher risk of having anti-TIF-1γ antibodies. 24 It is known that UV light increases the levels of Mi-2 in keratinocytes (the other antigen targeted more commonly in areas of high UV exposure), 25,26 and it will be important to test if UV light similarly affects TIF-1γ expression, structure, or subcellular localization in the skin.…”

Section: Discussionmentioning

confidence: 99%

Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis

Fiorentino

Kuo

Chung

et al. 2015

Journal of the American Academy of Dermatology

162

114

View full text Add to dashboard Cite

Background Antibodies against transcriptional intermediary factor (TIF)-1γ are associated with malignancy in dermatomyositis (DM). Identification of clinical findings associated with anti-TIF-1γ antibodies in DM is a high priority for both patient diagnosis and risk assessment. Objective We sought to define the clinical phenotype of patients with anti-TIF-1γ DM. Methods Using a novel, sensitive, and specific assay for anti-TIF-1γ antibodies, we retrospectively tested plasma from 134 adult patients with DM and examined associations between anti-TIF-1γ antibodies and particular clinical and laboratory features. Results In all, 55 (41%) patients had autoantibodies to TIF-1γ. Anti-TIF-1γ positive patients were less likely to have systemic features including interstitial lung disease, Raynaud phenomenon, and arthritis/arthralgia. Patients with TIF-1γ autoantibodies had more extensive skin involvement, and some patients manifested characteristic findings including palmar hyperkeratotic papules, psoriasis-like lesions and a novel finding of hypopigmented and telangiectatic (“red on white”) patches. Limitations This was a retrospective study from a single tertiary referral center. Conclusion TIF-1γ is the most commonly targeted DM-specific autoantigen in adults in a large US cohort. Although these patients tend to have less systemic involvement, their skin disease is often extensive and characteristic. Recognition of cutaneous findings in anti-TIF-1γ positive patients may allow more accurate and timely diagnosis and effective treatment of patients with DM.

show abstract

Section: Discussionmentioning

confidence: 99%

Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis

Fiorentino

Kuo

Chung

et al. 2015

Journal of the American Academy of Dermatology

162

114

View full text Add to dashboard Cite

show abstract

“…Patients present with classic skin eruptions particularly in sun-exposed areas alongside myositis, and it has been shown that surface ultra-violet (UV) irradiation intensity correlates with phenotype incidence, particularly in women [81,82]. However, a recent study suggests other factors other than UV influence the development of anti-Mi-2 DM, where autoAb frequency was significantly different in two Mexican cohorts, with similar UV exposures [83]. Both adults and children with anti-Mi-2 DM tend to have mild to moderate myositis and have less systemic disease with a low frequency of lung and joint disease [84].…”

Section: Anti-mi-2mentioning

confidence: 93%

The Clinical Features of Myositis-Associated Autoantibodies: a Review

Gunawardena

2015

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

The idiopathic inflammatory myopathies (IIM) are a group of autoimmune diseases traditionally defined by clinical manifestations including skeletal muscle weakness, skin rashes, elevated skeletal muscle enzymes, and neurophysiological and/or histological evidence of muscle inflammation. Patients with myositis overlap can develop other features including parenchymal lung disease, inflammatory arthritis, gastrointestinal manifestations and marked constitutional symptoms. Although patients may be diagnosed as having polymyositis (PM) or dermatomyositis (DM) under the IIM spectrum, it is quite clear that disease course between subgroups of patients is different. For example, interstitial lung disease may predominate in some, whereas cutaneous complications, cancer risk, or severe refractory myopathy may be a significant feature in others. Therefore, tools that facilitate diagnosis and indicate which patients require more detailed investigation for disease complications are invaluable in clinical practice. The expanding field of autoantibodies (autoAbs) associated with connective tissue disease (CTD)-myositis overlap has generated considerable interest over the last few years. Using an immunological diagnostic approach, this group of heterogeneous conditions can be separated into a number of distinct clinical phenotypes. Rather than diagnose a patient as simply having PM, DM or overlap CTD, we can define syndromes to differentiate disease subsets that emphasise clinical outcomes and guide management. There are now over 15 CTD-myositis overlap autoAbs found in patients with a range of clinical manifestations including interstitial pneumonia, cutaneous disease, cancer-associated myositis and autoimmune-mediated necrotising myopathy. This review describes their diagnostic utility, potential role in disease monitoring and response to treatment. In the future, routine use of these autoAb will allow a stratified approach to managing this complex set of conditions.

show abstract

“…However, clinical characteristics associated with anti-Mi-2 have not been studied extensively due to limited availability of the immunoassays and relatively low prevalence in PM/DM. One study from Mexico compared clinical features of anti-Mi-2 positive patients vs. others as the prevalence of anti-Mi-2 in this cohort was high (35 % in PM/DM, 45 % in DM) [77]. High CK level before treatment was noted in anti-Mi-2 (+) DM vs. anti-Mi-2 (−) DM (initial CK, >1000 IU/L, 100 vs. 52 %, P <0.0001; initial CK, >5000 IU/L, 54 vs. 14 %, P <0.005).…”

Section: Introductionmentioning

confidence: 99%

“…Although all studies showed the specificity of anti-Mi-2 for DM, reported prevalence of anti-Mi-2 in different studies is quite different even in the same country [77] as summarized in Table 6. Prevalence of anti-Mi-2 in DM varies 5–27 % in Italy and 2–19 % in Japan.…”

Section: Introductionmentioning

confidence: 99%

“…In a study that examined the role of environmental factors in the production of anti-Mi-2, prevalence was as low as 3.2 % (Montreal, Canada), 3.7 % (Warsaw, Poland), and 5.4 % (Bethesda, USA) in some areas while it was 60 % (Guatemala City, Guatemala), 36.1 % (Mexico City, Mexico), and 23.1 % (Santiago, Chile) in Central and South American countries [78]. Another study also showed 59 % prevalence of anti-Mi-2 in DM patients in Mexico City, but it was only 12 % in Guadalajara [77], suggesting a role of factors other than ultraviolet (UV). Correlation of UV radiation of the area with development of DM and production of anti-Mi-2 antibodies was suggested [78, 79].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy

Satoh

Tanaka

Ceribelli

et al. 2015

Clinic Rev Allerg Immunol

Self Cite

324

238

View full text Add to dashboard Cite

Autoantibodies specific for idiopathic inflammatory myopathy (myositis-specific autoantibodies (MSAs)) are clinically useful biomarkers to help the diagnosis of polymyositis/dermatomyositis (PM/DM). Many of these are also associated with a unique clinical subset of PM/DM, making them useful in predicting and monitoring certain clinical manifestations. Classic MSAs known for over 30 years include antibodies to Jo-1 (histidyl transfer RNA (tRNA) synthetase) and other aminoacyl tRNA synthetases (ARS), anti-Mi-2, and anti-signal recognition particle (SRP). Anti-Jo-1 is the first autoantibodies to ARS detected in 15–25 % of patients. In addition to anti-Jo-1, antibodies to seven other aminoacyl tRNA synthetases (ARS) have been reported with prevalence, usually 1–5 % or lower. Patients with any antiARS antibodies are associated with anti-synthetase syndrome characterized by myositis, interstitial lung disease (ILD), arthritis, Raynaud’s phenomenon, and others. Several recent studies suggested heterogeneity in clinical features among different anti-ARS antibody-positive patients and anti-ARS may also be found in idiopathic ILD without myositis. Anti-Mi-2 is a classic marker for DM and associated with good response to steroid treatment and good prognosis. Anti-SRP is specific for PM and associated with treatment-resistant myopathy histologically characterized as necrotizing myopathy. In addition to classic MSAs, several new autoantibodies with strong clinical significance have been described in DM. Antibodies to transcription intermediary factor 1γ/α (TIF1γ/α, p155/140) are frequently found in DM associated with malignancy while anti-melanoma differentiation-associated gene 5 (MDA5; CADM140) are associated with clinically amyopathic DM (CADM) complicated by rapidly progressive ILD. Also, anti-MJ/nuclear matrix protein 2 (NXP-2) and anti-small ubiquitin-like modifier-1 (SUMO-1) activating enzyme (SAE) are recognized as new DM-specific autoantibodies. Addition of these new antibodies to clinical practice in the future will help in making earlier and more accurate diagnoses and better management for patients.

show abstract

Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara

Cited by 69 publications

References 28 publications

Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis

Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis

The Clinical Features of Myositis-Associated Autoantibodies: a Review

A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy

Contact Info

Product

Resources

About